Extended Data Fig. 7: Human TFR cells are responsive to anti-PD-1 therapy.
From: Intratumoral follicular regulatory T cells curtail anti-PD-1 treatment efficacy
a, Heatmap comparing gene signatures of human tumor-infiltrating TFR cells pre- (n = 21 patients) and post- (n = 26 patients) anti-PD-1 therapy20. TFR cells from 5 patients (P2, P3, P12, P15, P20) receiving anti-PD-1 monotherapy were combined. IPA analysis of transcripts (n = 98) more highly expressed post anti-PD-1 treatment (right upper panel) and transcripts that overlap with CD28 signaling, ICOS-ICOSL signaling and T cell receptor signaling are highlighted (right lower panel and heatmap). b-i, Mice were s.c. inoculated with B16F10-OVA cells and treated with tamoxifen (days 5-8 and days 11-14) and anti-PD-1 Abs (day 9). Tumor volume (b,f), TFR cell frequencies (c, P = n.s., g, P = 0.035), eGFP cell frequencies (d, P = 0.0025, h, P = 0.0012) and FOXP3 frequencies (e,i) for n = 6 Foxp3eGFP-cre-ERT2 mice, n = 7 Foxp3eGFP-cre-ERT2/wt x Bcl6fl/fl mice, n = 7 Foxp3eGFP-cre-ERT2 mice and n = 5 Foxp3eGFP-cre-ERT2/wt mice. Data are mean + /− s.e.m., Significance for comparisons were computed using two-tailed Mann–Whitney test (b-i). Data in b-i are representative of two independent experiments.
